Back to Business Wire

Medincell

ISIN: FR0004065605

WKN: A2N6VA

About

Company Snapshot

New: Enable Investor Alerts

Be informed about new publications

New: AI Factsheet

Corporate News meets AI!
Content analysis and summary

Medincell · ISIN: FR0004065605 · Business Wire (ID: 20250209967526)

10 February 2025 08:00AM

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

Medincell (Paris:MEDCL):

ACCESS HERE THE FULL PRESS RELEASE

View source version on businesswire.com: https://www.businesswire.com/news/home/20250209967526/en/

Contact

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Visual performance / price development - Medincell

Smart analysis and research tools can be found here.

This publication was provided by our content partner Business Wire

BusinessWire

via BusinessWire - Newsfeed

BusinessWire

Contact:

101 California Street, 20th Floor San Francisco, CA, 94111 United States

+1.415.986.4422

Website

Twitter
Meta
Youtube
Instagram
LinkedIn
Contact
Newsfeed
RSS
Blog

Result of the AI analysis...

Tip: Registered users of the community can save the snippets in the user account.

Disclaimer:

This summary was created with the help of an AI technology. The goal is to bring out the core message of the company's message. The simplification of the statement can help to grasp the content of the message more quickly. The feature is experimental in nature. Do not use the information without verification. More information about Lab features can be found here.

Caution: Unverified adoption of previously unquality-assured information is not advised.

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

Contact

Newsletter